-
1.发明申请ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 有权抗体CD160特异性化合物的免疫和免疫应用可从mAb CL1-R2获得公开(公告)号：US20120003224A1
公开(公告)日：2012-01-05
申请号：US13175221
申请日：2011-07-01
CPC分类号： C07K16/2836 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/14 , C07K2317/75
摘要： The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.
摘要翻译： 本发明涉及抗CD160单克隆抗体（CL1-R2 CNCM I-3204）及其保守等价物的生物和医学应用。 更特别地涉及这些抗CD160化合物在EC血管生成和NK和T细胞因子产生领域中的应用。
-
公开(公告)号：US08268308B2
公开(公告)日：2012-09-18
申请号：US13008406
申请日：2011-01-18
IPC分类号： A61K39/395
CPC分类号： C07K16/3053 , A61K2039/505 , C07K16/28 , C07K2317/73
摘要： The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.
摘要翻译： 本发明涉及本发明人称为SC5的新型分子，其新颖的p140等位基因形式以及SC5和p140分子的生物学应用，特别是CTCL的诊断和治疗。
-
3.发明申请Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells 失效抗CD71单克隆抗体及其用于治疗恶性肿瘤细胞的用途公开(公告)号：US20060286030A1
公开(公告)日：2006-12-21
申请号：US11154262
申请日：2005-06-15
IPC分类号： A61K51/00 , A61K48/00 , A61K39/395 , C07K16/46 , C07K16/30 , A61K31/704 , A61K31/407 , A61K31/525
CPC分类号： A61K51/1027 , A61K47/6849 , C07K16/2881 , C07K2317/73
摘要： The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumor cells, especially metastatic cutaneous and uveal melanoma cells.
摘要翻译： 本发明提供了新颖的抗CD71单克隆抗体，特别是小鼠 - 人嵌合抗CD71单克隆抗体，其有利地与效应细胞相关联，用于触发ADCC机制。 抗CD71抗体以及含有它们的药物组合物可用于抑制增殖和/或杀死恶性肿瘤细胞，特别是转移性皮肤和葡萄膜黑素瘤细胞。
-
4.发明申请Anti-cd71 Monoclonal Antibodies and Uses Thereof for Treating Malignant Tumor Cells 失效抗cd71单克隆抗体及其用于治疗恶性肿瘤细胞的用途公开(公告)号：US20110311544A1
公开(公告)日：2011-12-22
申请号：US11922025
申请日：2006-06-14
IPC分类号： A61K39/395 , C12P21/00 , C12N5/10 , A61P35/00 , C12N15/63 , C07K16/18 , C07H21/04 , A61P37/00 , A61K35/00 , C12N5/00
CPC分类号： A61K51/1027 , A61K47/6849 , C07K16/2881 , C07K2317/73
摘要： The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
摘要翻译： 本发明提供了新颖的抗CD71单克隆抗体，特别是小鼠 - 人嵌合抗CD71单克隆抗体，其有利地与效应细胞相关联，用于触发ADCC机制。 抗CD71抗体以及含有它们的药物组合物可用于抑制增殖和/或杀死恶性肿瘤细胞，特别是转移性皮肤和葡萄膜黑素瘤细胞。
-
公开(公告)号：US20080274468A1
公开(公告)日：2008-11-06
申请号：US12050441
申请日：2008-03-18
CPC分类号： C07K16/3053 , A61K2039/505 , C07K16/28 , C07K2317/73
摘要： The invention relates to a novel molecule, termed SC5 by the inventors, to a novel allelic form of p140, and to the biological applications of SC5 and p140 molecules, notably in the diagnosis and therapy of CTCL.
摘要翻译： 本发明涉及本发明人称为SC5的新型分子，其新颖的p140等位基因形式以及SC5和p140分子的生物学应用，特别是CTCL的诊断和治疗。
-
公开(公告)号：US20060233793A1
公开(公告)日：2006-10-19
申请号：US10544031
申请日：2004-02-02
IPC分类号： A61K39/395
CPC分类号： C07K16/2803 , A61K2039/505
摘要： The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
摘要翻译： 本发明涉及使用BD16和/或BB18抗CD100抗体或其嵌合或人源化或人形式或其片段用于治疗或诊断中枢神经系统疾病，特别是髓鞘病症或 影响少突胶质细胞的疾病，如多发性硬化或HTLV-1相关性脊髓病或外周髓鞘细胞。
-
7.发明授权Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells 失效抗CD71单克隆抗体及其用于治疗恶性肿瘤细胞的用途公开(公告)号：US08409573B2
公开(公告)日：2013-04-02
申请号：US11922025
申请日：2006-06-14
IPC分类号： A61K39/00
CPC分类号： A61K51/1027 , A61K47/6849 , C07K16/2881 , C07K2317/73
摘要： The present invention provides novel anti-CD71 monoclonal antibodies, in particular mouse-human chimeric anti-CD71 monoclonal antibodies, advantageously associated to effector cells for triggering ADCC mechanisms. Anti-CD71 antibodies, as well as pharmaceutical compositions containing them, are useful for inhibiting proliferation and/or killing malignant tumour cells, especially metastatic cutaneous and uveal melanoma cells.
摘要翻译： 本发明提供了新颖的抗CD71单克隆抗体，特别是小鼠 - 人嵌合抗CD71单克隆抗体，其有利地与效应细胞相关联，用于触发ADCC机制。 抗CD71抗体以及含有它们的药物组合物可用于抑制增殖和/或杀死恶性肿瘤细胞，特别是转移性皮肤和葡萄膜黑素瘤细胞。
-
8.发明申请Angiogenic and immunoglobic applications of anti cd160 specific compounds obtainable from mab cl 1-r2 审中-公开抗CD160特异性化合物的血管生成和免疫应用可从mab cl 1-r2获得公开(公告)号：US20090317401A1
公开(公告)日：2009-12-24
申请号：US11659749
申请日：2005-08-09
IPC分类号： A61K39/395 , C07K16/28 , A61P9/10 , A61P35/00
CPC分类号： C07K16/2836 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/14 , C07K2317/75
摘要： The present invention relates to biological and medical application of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) an of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD 160 compounds in the fields of EC angiogenesis, and NK and T cytokine production
摘要翻译： 本发明涉及其保守等价物的抗CD160单克隆抗体（CL1-R2 CNCM I-3204）的生物和医学应用。 更特别地涉及这些抗CD 160化合物在EC血管发生，NK和T细胞因子产生领域中的应用
-
9.发明申请ANGIOGENIC AND IMMUNOLOGIC APPLICATIONS OF ANTI-CD160 SPECIFIC COMPOUNDS OBTAINABLE FROM mAb CL1-R2 审中-公开抗体CD160特异性化合物的免疫和免疫应用可从mAb CL1-R2获得公开(公告)号：US20140120110A1
公开(公告)日：2014-05-01
申请号：US13861749
申请日：2013-04-12
IPC分类号： C07K16/28
CPC分类号： C07K16/2836 , A61K2039/505 , C07K16/2803 , C07K16/2896 , C07K2317/14 , C07K2317/75
摘要： The present invention relates to biological and medical applications of an anti-CD160 monoclonal antibody (CL1-R2 CNCM I-3204) and of the conservative equivalents thereof. It more particularly relates to the applications of these anti-CD160 compounds in the fields of EC angiogenesis, and NK and T cytokine production.
摘要翻译： 本发明涉及抗CD160单克隆抗体（CL1-R2 CNCM I-3204）及其保守等价物的生物和医学应用。 更特别地涉及这些抗CD160化合物在EC血管生成和NK和T细胞因子产生领域中的应用。
-
10.发明授权公开(公告)号：US08067247B2
公开(公告)日：2011-11-29
申请号：US10544031
申请日：2004-02-02
IPC分类号： G01N33/53 , A61K39/395 , A61K39/00 , C07K16/00 , C12P21/08
CPC分类号： C07K16/2803 , A61K2039/505
摘要： The invention relates to the use a BD16 and/or BB18 anti-CD100 antibody or of a chimeric or humanized or human form thereof, or a fragment thereof, for the therapy or diagnosis of a central nervous system disorder, more particularly a myelin disorder or a disease that affects oligodendrocytes, such as multiple sclerosis or HTLV-1 associated myelopathy or peripheral myelinating cells.
摘要翻译： 本发明涉及使用BD16和/或BB18抗CD100抗体或其嵌合或人源化或人形式或其片段用于治疗或诊断中枢神经系统疾病，特别是髓鞘病症或 影响少突胶质细胞的疾病，如多发性硬化或HTLV-1相关性脊髓病或外周髓鞘细胞。
-
-
-
-
-
-
-
-
-
搜索结果
25 条记录 (耗时 0.022 秒)
